|2011 update of the drug resistance mutations in HIV-1|
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
|Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update|
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
|2017 update of the drug resistance mutations in HIV-1|
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
|Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel|
MS Hirsch, HF Günthard, JM Schapiro, FB Vézinet, B Clotet, SM Hammer, ...
Clinical Infectious Diseases 47 (2), 266-285, 2008
|Update of the Drug Resistance Mutations in HIV-1: 2005|
VA Johnson, F Brun-Vézinet, B Clotet, B Conway, D Pillay, J Schapiro, ...
Top. HIV Med 14 (3), 125-130, 2006
|British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008|
BG Gazzard, J Anderson, A Babiker, M Boffito, G Brook, G Brough, ...
HIV medicine 9 (8), 563-608, 2008
|Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global …|
RK Gupta, MR Jordan, BJ Sultan, A Hill, DHJ Davis, J Gregson, ...
The Lancet 380 (9849), 1250-1258, 2012
|Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …|
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
|HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance|
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
AIDS (London, England) 21 (2), 215, 2007
|Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration|
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
|Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study|
A Banerjee, L Pasea, S Harris, A Gonzalez-Izquierdo, A Torralbo, ...
The Lancet 395 (10238), 1715-1725, 2020
|Update of the drug resistance mutations in HIV-1: March 2013|
VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
|Digital technologies in the public-health response to COVID-19|
J Budd, BS Miller, EM Manning, V Lampos, M Zhuang, M Edelstein, ...
Nature medicine 26 (8), 1183-1192, 2020
|British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy|
S Collins, M Fisher, M Johnson, S Khoo, C Leen, C Loveday, G Moyle, ...
|Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and …|
RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri, V von Wyl, S Yerly, VD Lima, ...
The Lancet infectious diseases 9 (7), 409-417, 2009
|Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups|
S Hué, D Pillay, JP Clewley, OG Pybus
Proceedings of the National Academy of Sciences 102 (12), 4425-4429, 2005
|HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression …|
RK Gupta, J Gregson, N Parkin, H Haile-Selassie, A Tanuri, LA Forero, ...
The Lancet infectious diseases 18 (3), 346-355, 2018
|Principles and practice of clinical virology|
John Wiley & Sons, 2009
|HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy|
S Hué, JP Clewley, PA Cane, D Pillay
Aids 18 (5), 719-728, 2004
|Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials|
R Gupta, A Hill, AW Sawyer, D Pillay
Clinical infectious diseases 47 (5), 712-722, 2008